The use of a computerized database to monitor vaccine safety in Viet Nam. by Ali, Mohammad et al.
Ochiai, RL; Wang, X; von Seidlein, L; Yang, J; Bhutta, ZA; Bhat-
tacharya, SK; Agtini, M; Deen, JL; Wain, J; Kim, DR; Ali, M; Acosta,
CJ; Jodar, L; Clemens, JD (2005) Salmonella paratyphi A rates, Asia.
Emerging infectious diseases, 11 (11). pp. 1764-6. ISSN 1080-6040
Downloaded from: http://researchonline.lshtm.ac.uk/10269/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
Salmonella
Paratyphi A Rates,
Asia
R. Leon Ochiai,* XuanYi Wang,* 
Lorenz von Seidlein,* Jin Yang,† 
Zulfiqar A. Bhutta,‡ Sujit K. Bhattacharya,§
Magdarina Agtini,¶ Jacqueline L. Deen,* 
John Wain,# Deok Ryun Kim,* Mohammad Ali,*
Camilo J. Acosta,* Luis Jodar,* 
and John D. Clemens*
Little is known about the causes of enteric fever in
Asia. Most cases are believed to be caused by Salmonella
enterica serovar Typhi and the remainder by S. Paratyphi
A. We compared their incidences by using standardized
methods from population-based studies in China,
Indonesia, India, and Pakistan. 
Enteric fever still causes substantial illness and death inmany parts of the world, especially in poorer nations.
Salmonella enterica serovar Typhi is believed to cause
most enteric fever episodes, and a smaller portion are
caused by S. Paratyphi (1–3). This assumption, however,
may no longer be true. Since 1999, more S. Paratyphi A
than S. Typhi strains have been isolated in the province of
Guangxi, southeastern China (4). Increasing isolation rates
of S. Paratyphi A has also been reported from India (5).
This finding has 2 major implications for the prevention of
enteric fever. First, licensed typhoid fever vaccines (Vi
polysaccharide and live oral Ty21a) do not protect against
infections caused by S. Paratyphi A, and they may become
less useful in controlling enteric fever in regions of Asia.
Second, transmission and risk factors for S. Typhi and S.
Paratyphi are different in Indonesia (6), so reduction
strategies effective against S. Typhi may not protect
against S. Paratyphi. Since little is known about the current
cause of enteric fever in Asia, we compared S. Typhi and
S. Paratyphi A incidence from study sites in China,
Indonesia, India, and Pakistan by using standardized epi-
demiologic and laboratory methods (7).
The Study
After a baseline census, surveillance was conducted in
study sites in Karachi, Pakistan; Calcutta, India; North
Jakarta, Indonesia; and Hechi City, China, for 12 months
to identify typhoid and paratyphoid cases from specific
populations at high risk (Table). None of the sites had spe-
cific enteric fever control programs in the past. Hechi City,
China, is located in Guangxi Zhuang Autonomous Region
where Vi vaccines had been used in the past (8,9); howev-
er, no such intervention had taken place in Hechi City. The
closest county with a vaccination program was ≈80 km
away and vaccinated only students (29,000 doses in 2001).
During the surveillance period, persons with fever who
lived in each study area were requested to visit participat-
ing healthcare providers. We collected 5–10 mL blood
from adults with fever >3 days’ duration into Bactec bot-
tles (Becton Dickinson, Franklin Lakes, NJ, USA). We
collected 3–8 mL from children with fever >3 days’ dura-
tion into Pediatric Bactec bottles. The bottles were incu-
bated at 37°C for 7–10 days and visually checked for
growth every day. Bottles were subcultured on
MacConkey agar on days 1, 2, 4, and 7 or when turbidity
was detected. Suspected colonies were screened by using
Kligler iron agar, sulfide-indole-motility medium, urea
agar, and citrate. Colonies that showed biochemical reac-
tions suggestive of salmonellae were confirmed serologi-
cally by Felix-Widal tube agglutination test with specific
O and H antisera (Becton Dickinson). All Salmonella iso-
lates were confirmed at a reference laboratory (University
of Oxford, Wellcome Trust Clinical Research Unit, Ho Chi
Minh City, Vietnam).
Incidence rates were calculated by using age-specific
denominators of the population living in the catchment
area based on the study census. We assumed that each per-
son living in the study area contributed 12 months of per-
son-time to the denominator. The number of disease
episodes in eligible individuals was used as the numerator. 
Each study received individual approval from the local
ethical committees, the institutional review board of the
International Vaccine Institute (Seoul, Korea), and the
Secretariat Committee for Research Involving Human
Subjects, World Health Organization (Geneva,
Switzerland).
During the surveillance period, 285 S. Typhi episodes
and 84 S. Paratyphi A episodes were detected at the 4 sites
(Table). In Indonesia, 14% of enteric fever episodes were
caused by S. Paratyphi A, in Pakistan 15%, in India 24%,
and in China 64% (Figure). The highest S. Typhi incidence
was observed in Pakistan (394/100,000/year), and the low-
est S. Typhi incidence was found in China
(15.2/100,000/year). The highest S. Paratyphi A incidence
was also seen in Pakistan (72/100,000/year), and the low-
est S. Paratyphi A incidence was seen in Indonesia
(13.7/100,000/year).
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Conclusions
The perception that a small proportion of enteric fever
cases are caused by S. Paratyphi A is probably no longer
true in many regions of Asia, especially in southeast China,
where S. Paratyphi A is already more frequently isolated
than is S. Typhi. This finding could be signaling the emer-
gence of S. Paratyphi A as a pathogen in Asia. Comparison
of S. Paratyphi A incidence during the last decade is need-
ed to prove this hypothesis. However, none of the sites
have comparable surveillance data on S. Paratyphi A over
time. An alternative explanation is that the incidence of S.
Typhi is decreasing. Previous reports from vaccine trials
have shown successful control of S. Typhi but no changes
in the incidence of S. Paratyphi A (8,10,11). Nonetheless,
the reversal of the proportion of S. Typhi and S. Paratyphi
A infections in Hechi City, China, is unlikely to be the
result of typhoid fever control in other counties, consider-
ing the distance and oral-fecal transmission route of S.
Typhi and S. Paratyphi A. 
Economic growth in Asia has also resulted in improved
water supply, sanitation, and hygiene; however, we have
no reason to assume selective reduction only for transmis-
sion of S. Typhi. The incidence of typhoid fever per
100,000 in the different countries follows the same pattern
as mean gross national income (2003) and the mortality
ranking for children <5 years (12). 
The sensitivity of blood culture for S. Typhi is well
described, but little is known about S. Paratyphi A.
Bacterial loads during infection are probably similar for
both S. Typhi and S. Paratyphi A (J. Wain, unpub. data).
Furthermore, S. Paratyphi A had been rarely isolated in
these regions, which suggests that the increase in isolation
rate of S. Paratyphi A is possibly caused by an increase in
the number of cases of enteric fever caused by S.
Paratyphi A rather than any bias toward blood culture–
positive disease.
Besides the limitation that our studies only describe a
12-month period, the population varied between sites. In
Pakistan, only children 2–16 years of age were included.
As S. Paratyphi A infections are more frequently observed
in adults, including older patients in surveillance may
increase S. Paratyphi A incidence rates reported from
Pakistan.
In China and India, countries with the largest popula-
tions in the world, S. Paratyphi A is the causal agent for a
substantial proportion of enteric fever episodes that can-
not be distinguished clinically from typhoid fever
episodes. While similar treatment strategies may work for
both organisms, future enteric fever prevention strategies
in Asia must focus on S. Paratyphi A as well as on S.
Typhi, especially when considering the emergence of
drug-resistant strains (13–15). Future vaccination strate-
gies should include bivalent vaccines that protect against
S. Typhi as well as S. Paratyphi A. Otherwise, the protec-
tive effectiveness of typhoid fever vaccines (Vi, Ty21a)
against enteric fever may diminish, which could result in
a loss of public confidence and decrease public willing-
ness to be vaccinated.
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Figure. Incidence of Salmonella enterica serovar Typhi and S.
Paratyphi A in 4 Asian countries.
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